Interview with Amit Mehta, Managing Director, S. Amit & Co
India has experienced tremendous growth in its chemical and pharmaceutical industries. Being active for many years in the industry now, how have you seen the market evolving? S. Amit has…
Address: 101-A Neelam Centre, 249-B Hind Cycle Road, Worli, Mumbai 400 030, India
Tel: +91 22 4001 3000
S. Amit Speciality Chemicals Pvt. Ltd. is a leading full-service Chemistry Solutions provider in India delivering products and services in the areas of speciality chemicals, intermediates and performance chemicals for diverse applications including pharmaceuticals, agrochemicals, polymers & plastics, and paints and coating.
Over the last six decades, the Company has transitioned from representing international laboratory chemical suppliers to marketing 1 or 2 steps of chemistries to supplying advanced intermediates and performance chemicals such as reducing agents, resolving agents, encapsulated catalysts, etc. Focussed on its broad-based relationships with both customers and suppliers, the objective has always been to add value to the chemical supply chain for both parties.
Today, as an integrated solutions provider, the S. Amit Group of Companies focuses on offering a full range of supply chain services including – representation of manufacturers, global and local sourcing, distribution, virtual manufacturing, and identifying problems and recommending innovative chemical solutions. This allows our customers and suppliers to effectively extract value from the supply chain based on their needs and the market situation.
In January 2011, S. Amit acquired Reaxa U.K., a company actively involved in developing and supplying encapsulated metal catalysts for synthetic organic chemistry.
Through its various group companies, the S. Amit Group provides
Indenting
Local Sales and Distribution
Exports
Virtual Manufacturing Services
Products and services are branded through the following group companies – S. Amit, Finorga,
Chem Amit, Perfo Chem and Brom Chem
The S. Amit Group also has a joint venture company, Diamines & Chemicals Ltd. that manufactures piperazine at its plant in Baroda, Gujarat.
India has experienced tremendous growth in its chemical and pharmaceutical industries. Being active for many years in the industry now, how have you seen the market evolving? S. Amit has…
Before moving into the company’s strategy, can you give our readers an idea of what role Boehringer Ingelheim India plays within the Group’s worldwide operations? Within the Boehringer Ingelheim Group,…
To start off, can you tell us how you have seen the pharmaceutical industry developing in India? Has the perception of India by big pharma changed over the years? First…
If we look back at the conditions under which you founded Biocon in 1978, we see a young woman with a seed capital of only Rs. 10,000 in a garage…
You have already publicly announced that, despite being late in India, Lonza has been increasingly looking into expanding in the Indian market. First of all, what do you think sparked…
A catalyst of India’s shifting industry dynamics has been the sector’s M&A activity. We already saw majors such as Piramal going to Abbott and Ranbaxy to Daiichi-Sankyo… And while Andrew…
With the recent event “Vibrant Gujarat”, the state of Gujarat aimed to showcase the region’s opportunities and advanced infrastructure, hosting 1,400 delegates from 101 countries as well as several presentations…
You founded Calyx in 1979 with a three-person team. At the time, you were just 21 years old! What was the vision behind the creation of the company? Essentially, the…
You joined Wockhardt in 2000; you became a member of the board in 2006, and were appointed managing director in 2009. The Indian industry has undergone many changes in the…
Glenmark may be poised to release India’s first novel drug, from the in-licensed, anti-diarrheal molecule Crofelemer. Crofelemer has successfully complete Phase III trials, and you are readying to release it…
Since we last met in 2006, the Indian pharmaceutical industry has been doing very well indeed, as a very large number of drugs came off patent. This trend will continue…
Since we last met in 2006, the Indian pharmaceutical industry has been doing very well indeed, as a very large number of drugs came off patent. This trend will continue…
Our last report on India dates back to 2006, right after the Patent Law was passed. What developments have you seen happening in the industry since then? There has been…
See our Cookie Privacy Policy Here
